激素受体和cerbB-2在新辅助化疗乳腺癌组织中的表达及临床意义

Clinical significance hormone receptor(ER/PR), cerbB-2 of neoadjuvant chemotherapy in breast cancer

目的:探讨雌/孕激素受体(ER/PR)和eerbB-2在新辅助化疗乳腺癌组织中的表达及临床意义。方法: 采用新辅助化疗方案(CEF或CTF方案)治疗89例乳腺癌患者,用免疫组织化学法检测ER/PR及cerbB-2在乳腺癌组织中的表达情况。结果:89例新辅助化疗总有效率达89.9%,其中完全缓解29例(32.6%),部分缓解51例(57.3%),病理完全缓解(pCR)17.9%,疾病稳定9例(10.1%),无恶化病例;激素受体表达阴性者病理完全缓解率达27.7%,而激素受体阳性表达者病理完全缓解率仅为7.1%(P<0.05),cerbB-2表达与化疗疗程无关。结论: 激素受体阴性者对新辅助化疗的敏感性较高,激素受体可能成为评价和判断新辅助化疗乳腺癌患者临床疗效和预后的重要参考指标。

Objective： To explore the expression and its clinical significance of hormone receptor and cerbB-2 in breast cancer tissue received neoadjuvant chemotherapy. Methods： The estrogen receptor（ER）, progesterone recepter（PR） and cerbB-2 in breast cancer tissue of 89 patients received neoadjuvant chemotherapy were detected by immunohistochemical method, and analysed the relation with response of neoadjuvant chemotherapy. Results： The overall response rate of neoadjuvant chemotherapy on breast cancer was 89.9%, of which the complete response was 32.6%, partial response was 57.3%, pathological complete response was 17.9%, disease stable 10.5%. Hormonal receptor expressions was significantly related to treatment response, the pathological complete response rate was 27.2% in ER/PR negative tumors, but it was 7.1% in the positive tumors （P〈0.05）. No correlation was observed between the treatment response and cerbb-2 expression. Conclusions： There has higher sensitivity to neoadjuvant chemotherapy in hormonal receptor negative tumors. The hormone receptor of breast cancer in neoadjuvant chemotherapy may be provide important index in decision sensitivity of chemotherapy and clinical evaluation.